

14230 US PTO
022604Attorney Docket No. 99-16D3
Express Mail Label No. EV331816083US
Date of Deposit: February 26, 2004IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
APPLICATION AND FEE TRANSMITTALO
10/787442
22856 US PTO
022604

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is a request for filing a continuation patent application divisional patent application

under 37 C.F.R. §1.53(b), of pending prior application Serial No. 09/522,217, issued as U.S. Patent No. 6,307,024, on October 23, 2001, incorporated herein by reference, and claims benefit to U.S. Provisional Application Nos. 60/123,547, filed on March 9, 1999; 60/123,904, filed on March 11, 1999; and 60/142,013, filed on July 1, 1999, entitled CYTOKINE ZALPHA11 LIGAND FUSION PROTEINS.

Prior Examiner: Seharaseyon, J. Prior Art Unit: 1647

Enclosed are the following papers:

- 193 pages of specification
 3 sheets of Declaration and Power of Attorney
 5 sheets of Figures
 56 pages of sequence listing
Information Disclosure Statement and PTO-1449
 A Preliminary Amendment is enclosed.
- The prior application is assigned of record to ZymoGenetics, Inc. recorded on August 13, 2001, Reel 012101, Frame 0229.
- Address all future communications to Deborah A. Sawislak, Patent Department, ZymoGenetics, Inc., 1201 Eastlake Avenue East, Seattle, Washington 98102.
- Enclosed is a ASCII Computer Disk Sequence pursuant to 37 C.F.R. 1.821(f). It is believed that the content of the paper sequence listing and the computer readable sequence listing are the same.

CALCULATION OF APPLICATION FEE

Claim Type	No. Filed	Less	Extra	Extra Rate	Fee
Total	9	-20	0	\$9.00	\$000.00
Independent	6	-3	3	\$43.00	\$129.00
		Basic Fee			\$385.00
		Multiple Dependency Fee			\$000.00
		If Applicable (\$145.00)			\$000.00
		Total Filing Fee			\$514.00

Applicants claim small entity status. Please charge ZymoGenetics, Inc., Deposit Account No. 26-0290 as follows:

- Filing fee, estimated to be \$514
- Assignment recording fee
- Any additional fees associated with this paper or during the pendency of this application.
- The issue fee set in 37 C.F.R. 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

A copy of these sheets is enclosed.

Respectfully submitted,



Deborah A. Sawislak
Registration No. 37,438

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent Application for
CYTOKINE ZALPHA11 LIGAND FUSION PROTEINS

Applicants: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond

Sir:


Express Mail Label No. EV331816083US

Date of Deposit February 26, 2004

I hereby certify that the following attached paper(s) or fee

1. Return Post card
2. Application And Fee Transmittal (in duplicate)
3. Patent Application (193 pages)
4. Figures (5 sheets of drawings)
5. Copy of Executed Declaration and Power of Attorney
6. Sequence Listing (56 pages)
7. Letter Regarding Sequence Listing
8. Letter Identifying Changes
9. Information Disclosure Statement and PTO-1449

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above, addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Kim M. Goplen

ZymoGenetics, Inc.
1201 Eastlake Avenue East
Seattle, WA 98102
(206) 442-6600

Express Mail Label No. EV331816083US

PATENT APPLICATION
File No.: 99-16D3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
For: CYTOKINE ZALPHA11 LIGAND FUSION PROTEINS
Filed: February 26, 2004

LETTER IDENTIFYING CHANGES

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The specification submitted herewith has been amended from the parent application as follows:

Page 1 has been amended to include a Cross-Reference to Related Applications.

Claims 3-5 were originally designated as Group II in the Restriction Requirement of the parental U.S. Patent Application Serial No. 09/522,217. The claims have been amended and renumbered. Claims 1, 2, 6-9 are newly added. The claims are directed only to subject matter disclosed in the prior application.

Applicants have amended the specification to reflect changes to the status of the parental patent application. Applicants have also amended the specification to correct inadvertent typographical errors. On page 26, at line 24, and page 40, at line 30, amino acid residue 33 was amended to recite amino acid residue 32. Support for the correction can be found, for example, on page 10, at lines 14-17, and page 42, at lines 10-14, where the secretory signal sequence is disclosed as being amino acid residues 1-31 of SEQ ID NO:2, and the mature polypeptide is amino acid residues 32-162 of SEQ ID NO:2. On page 101, at

lines 5-9, the specification has been amended to correct the inadvertent error where mg/ml should read μ g/ml.

The instant continuing patent application includes a new set of claims. The claims are directed only to subject matter disclosed in the prior application.

No new matter has been added.

Respectfully submitted,



Deborah A. Sawislak
Registration No. 37,438